Interim report for January - June 2021

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

September 13, 2021Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
August 24, 2021Interim report January – June 2021
August 17, 2021Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021
July 20, 2021The rights issue is registered and the trading in Paid Subscription Shares ceases
June 22, 2021Outcome in Promore Pharma’s rights issue

More Press Releases

Interim report January – June 2021

Promore Pharma AB (publ) published its interim report for the second quarter 2021 on August 24 2021.

Read the report

Calendar

November 23, 2021Interim report January – September 2021

More Events

Promore Pharma in Media

Here we present media releases, interviews, images and videos.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate of approximately 6 percent and is expected to reach USD 12 billion in 2024.